Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
APM
Upturn stock ratingUpturn stock rating

Aptorum Group Ltd Class A (APM)

Upturn stock ratingUpturn stock rating
$0.91
Last Close (24-hour delay)
Profit since last BUY-23.53%
upturn advisory
WEAK BUY
BUY since 18 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: APM (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

2 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $80

1 Year Target Price $80

Analysts Price Target For last 52 week
$80Target price
Low$0.46
Current$0.91
high$4.74

Analysis of Past Performance

Type Stock
Historic Profit -90.26%
Avg. Invested days 17
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 6.94M USD
Price to earnings Ratio -
1Y Target Price 80
Price to earnings Ratio -
1Y Target Price 80
Volume (30-day avg) 2
Beta -0.32
52 Weeks Range 0.46 - 4.74
Updated Date 06/30/2025
52 Weeks Range 0.46 - 4.74
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.78

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -8.33%
Return on Equity (TTM) -30.62%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 9420828
Price to Sales(TTM) 23.35
Enterprise Value 9420828
Price to Sales(TTM) 23.35
Enterprise Value to Revenue 31.22
Enterprise Value to EBITDA -0.45
Shares Outstanding 5346820
Shares Floating 3404715
Shares Outstanding 5346820
Shares Floating 3404715
Percent Insiders 19.48
Percent Institutions 1.76

Analyst Ratings

Rating 2
Target Price 80
Buy 1
Strong Buy 1
Buy 1
Strong Buy 1
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Aptorum Group Ltd Class A

stock logo

Company Overview

overview logo History and Background

Aptorum Group Limited was founded in 2016. It is a pharmaceutical company focused on developing and commercializing novel therapeutics to address unmet medical needs.

business area logo Core Business Areas

  • Therapeutic Development: Develops pharmaceutical products for various diseases using novel technologies.
  • Drug Discovery: Identifies and validates potential drug targets for future therapeutics.
  • Commercialization: Focuses on the commercialization of products through strategic collaborations and partnerships.

leadership logo Leadership and Structure

The leadership team consists of experienced professionals in the pharmaceutical and biotech industries. The organizational structure includes departments for research and development, clinical trials, regulatory affairs, and commercial operations.

Top Products and Market Share

overview logo Key Offerings

  • ALS-4: A small molecule anti-virulence approach targeting Staphylococcus aureus infections. No market share data is available for this specific product as it is still in development stages. Competitors are companies developing other anti-infectives.
  • SACT-1: A novel drug for oncology indications. No market share data is available for this specific product as it is still in development stages. Competitors are companies with cancer therapies in similar stages of development.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is characterized by intense competition, high R&D costs, and stringent regulatory requirements. The market is driven by an increasing global population, rising prevalence of chronic diseases, and technological advancements.

Positioning

Aptorum Group is positioned as an innovative pharmaceutical company focusing on developing novel therapies to address unmet medical needs. Its competitive advantages may include its innovative technologies and strategic partnerships.

Total Addressable Market (TAM)

The specific TAM varies depending on the therapeutic area. Aptorum Group is focusing on niche areas within larger markets. Specific TAM figures are not publicly available for Aptorum Group's target indications.

Upturn SWOT Analysis

Strengths

  • Innovative technology platforms
  • Experienced management team
  • Focus on unmet medical needs

Weaknesses

  • Limited financial resources
  • Early-stage development pipeline
  • Dependence on partnerships

Opportunities

  • Strategic collaborations and partnerships
  • Expansion into new therapeutic areas
  • Out-licensing of technologies

Threats

  • Competition from larger pharmaceutical companies
  • Regulatory hurdles
  • Clinical trial failures

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • PFE
  • MRK

Competitive Landscape

Aptorum Group faces significant competition from established pharmaceutical companies with greater resources and larger market shares. Aptorum Group's success depends on its ability to develop and commercialize differentiated products.

Growth Trajectory and Initiatives

Historical Growth: Aptorum Group's historical growth has been focused on building its pipeline and technology platforms.

Future Projections: Future growth is dependent on the successful development and commercialization of its products.

Recent Initiatives: Recent initiatives include advancing clinical trials, securing partnerships, and expanding its intellectual property portfolio.

Summary

Aptorum Group is a small pharmaceutical company focused on developing novel therapeutics. The company faces significant challenges in securing funding, navigating regulatory hurdles, and competing with larger players. Its success is highly dependent on its pipeline candidates progressing through clinical trials and reaching commercialization, which makes the stock very speculative. While it has a compelling value proposition in unmet needs, it needs to execute and maintain its funding strategy to continue to compete.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings
  • Industry Reports
  • Analyst Reports

Disclaimers:

The data and analysis provided are for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. This information is not financial advice, and you should consider a professional before making investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Aptorum Group Ltd Class A

Exchange NASDAQ
Headquaters -
IPO Launch date 2018-12-18
Founder, CEO & Executive Director Mr. Chung Yuen Huen
Sector Healthcare
Industry Biotechnology
Full time employees 1
Full time employees 1

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.